You are here

Article Text

Article menu
Download PDFPDF
Editorial commentary
Neurofilament light for measuring the treatment efficacy in clinical practice: are we there yet?
  1. Lenka Novakova1,2
  1. 1 Institute of Neuroscience and Physiology, University of Gothenburg Sahlgrenska Academy, Gothenburg, Sweden
  2. 2 Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden
  1. Correspondence to Dr Lenka Novakova, Institute of Neuroscience and Physiology, University of Gothenburg Sahlgrenska Academy, Gothenburg 405 30, Sweden; lenka.novakova{at}vgregion.se

https://doi.org/10.1136/jnnp-2019-321615

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Phase 4 open-label study on dimethyl fumarate in MS investigating the dynamics of blood neurofilament as treatment response biomarker

    Neurofilament light (NFL) is a cytoskeleton protein of myelinated axons and is one of the most studied biomarkers of disease activity and treatment response in patients with multiple sclerosis (MS), and the most promising biomarkers for the use in MS standard care. NFL levels increase in cerebrospinal fluid (CSF) and blood after axonal injury in MS and other neurological disorders, and the increase is proportional to the damage.1 The single molecule array (SIMOA) technology used to analyse NFL in the study by Sejbaek et al 2 is able to detect NFL at ultralow levels in the blood. This allows measuring NFL easily and regularly. The evidence for NFL as a disease activity and treatment response …

    View Full Text

    Footnotes

    • Contributors The manuscript was written by LN.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient consent for publication Not required.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles